User profiles for Tanya Golubchik

Tanya Golubchik

Sydney Institute for Infectious Diseases, School of Medical Sciences, University of Sydney
Verified email at sydney.edu.au
Cited by 11575

[HTML][HTML] Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort …

…, H Adams, C Fraser, T Golubchik… - The Lancet Infectious …, 2022 - thelancet.com
Background The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March,
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …

[PDF][PDF] Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

…, JP McKenna, H Adams, C Fraser, T Golubchik… - Cell, 2021 - cell.com
Global dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G
are suggestive of a selective advantage but may also be due to a random founder effect. We …

[HTML][HTML] Diverse Sources of C. difficile Infection Identified on Whole-Genome Sequencing

…, L O'Connor, CLC Ip, T Golubchik… - … England Journal of …, 2013 - Mass Medical Soc
Background It has been thought that Clostridium difficile infection is transmitted predominantly
within health care settings. However, endemic spread has hampered identification of …

SARS-CoV-2 within-host diversity and transmission

…, D Bonsall, C Fraser, T Golubchik - Science, 2021 - science.org
INTRODUCTION Genome sequencing at an unprecedented scale during the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is helping to track spread of the …

A highly virulent variant of HIV-1 circulating in the Netherlands

…, F Blanquart, L Ferretti, A Gall, M Hall, T Golubchik… - Science, 2022 - science.org
We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred
nine individuals with this variant had a 0.54 to 0.74 log 10 increase (ie, a ~3.5-fold to 5.5-…

Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event

T Golubchik, AB Brueggemann, T Street, RE Gertz Jr… - Nature …, 2012 - nature.com
Streptococcus pneumoniae ('pneumococcus') causes an estimated 14.5 million cases of
serious disease and 826,000 deaths annually in children under 5 years of age 1 . The highly …

[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …

KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus… - The Lancet, 2021 - thelancet.com
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

[HTML][HTML] Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis

O Ratmann, MK Grabowski, M Hall, T Golubchik… - Nature …, 2019 - nature.com
To prevent new infections with human immunodeficiency virus type 1 (HIV-1) in sub-Saharan
Africa, UNAIDS recommends targeting interventions to populations that are at high risk of …

[PDF][PDF] Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7

…, SC Robson, NJ Loman, TR Connor, T Golubchik… - Cell reports, 2021 - cell.com
We report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike ΔH69/V70
in multiple independent lineages, often occurring after acquisition of receptor binding motif …

[HTML][HTML] Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study

…, H Adams, C Fraser, T Golubchik… - The Lancet Public …, 2021 - thelancet.com
Background The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in
England. We aimed to investigate whether increases in the proportion of infections with this …